- Home
- STWD vs IBRX Comparison
STWD vs IBRX Comparison
Compare STWD & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STWD | IBRX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | 691 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 8.0B |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | STWD | IBRX |
|---|---|---|
| Price | $17.60 | $8.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $20.13 | $12.57 |
| AVG Volume (30 Days) | 3.0M | ★ 31.4M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 10.88% | N/A |
| EPS Growth | 4.55 | ★ 38.71 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,844,289,000.00 | $113,288,000.00 |
| Revenue This Year | $283.44 | $88.57 |
| Revenue Next Year | $17.66 | $146.98 |
| P/E Ratio | $15.37 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $16.59 | $1.83 |
| 52 Week High | $20.99 | $12.43 |
Technical Indicators
Market Signals| Indicator | STWD | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 53.23 |
| Support Level | N/A | $2.27 |
| Resistance Level | $18.56 | $12.43 |
| Average True Range (ATR) | 0.32 | 0.98 |
| MACD | -0.02 | -0.31 |
| Stochastic Oscillator | 21.53 | 14.16 |
Price Performance
Historical ComparisonAbout STWD STARWOOD PROPERTY TRUST INC. Starwood Property Trust Inc.
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment, and Investing & Servicing Segment. The company generates the majority of its revenue from the Commercial and Residential Lending Segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.